In This Section

Press Program 2023

The AACR Annual Meeting 2023 press program included three in-person press conferences featuring 10 newsworthy studies from the Annual Meeting. The AACR also issued news releases on four additional abstracts.

Press Conference I: Sunday, April 16, 2023

AACR Annual Meeting Clinical Trials Committee Cochair Timothy Yap, MBBS, PhD, The University of Texas MD Anderson Cancer Center, moderated the press conference.

View Press Conference I

The following studies were presented:

Adding a Personalized mRNA Cancer Vaccine to Immunotherapy May Prolong Recurrence-free Survival in Patients With High-risk Melanoma

  • Presented by Jeffrey Weber, MD, PhD, NYU Langone Perlmutter Cancer Center, NYU Grossman School of Medicine

Adjuvant Treatment With Atezolizumab and Bevacizumab May Delay Recurrence After Surgical Resection in Patients With Liver Cancer

  • Presented by Pierce Chow, FRCS(E), PhD, National Cancer Centre Singapore, Singapore General Hospital, Duke-NUS Medical School

Durvalumab-based Treatment Before and After Surgery Improved Outcomes for Patients With Resectable Non-small Cell Lung Cancer

  • Presented by John V. Heymach, MD, PhD, The University of Texas MD Anderson Cancer Center

First-line Pembrolizumab Plus Chemotherapy May Benefit Patients with Advanced Biliary Tract Cancers

  • Presented by Robin “Katie” Kelley, MD, Helen Diller Family Comprehensive Cancer Center at University of California, San Francisco

PRESS CONFERENCE II: Monday, April 17, 2023

Lisa Newman, MD, MPH, NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine, and member of the AACR Board of Directors, moderated the press conference.

View press conference II

The following studies were presented:

Colorectal Cancer Patients With African Ancestry Had Fewer Clinically Actionable Alterations Than White Patients

  • Presented by Henry Walch, MS, Memorial Sloan Kettering Cancer Center

New Bispecific Antibody Demonstrates Clinical Activity in Patients With Multiple Myeloma

  • Presented by Attaya Suvannasankha, MD, Indiana University School of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Awareness of the Link Between HPV and Cervical Cancer Has Declined

  • Presented by Eric Adjei Boakye, PhD, Henry Ford Health

PRESS CONFERENCE: Tuesday, April 18, 2023

AACR Annual Meeting Clinical Trials Committee Cochair Shivaani Kummar, MD, Oregon Health & Science University Knight Cancer Institute, moderated the press conference.

View press conference III

The following studies were presented:

Olaparib Plus Ceralasertib May Benefit Pediatric Cancer Patients With DNA Repair-deficient Tumors

  • Presented by Susanne Gatz, MD, PhD, Institute of Cancer and Genomic Sciences of the University of Birmingham

An Investigational Deep Learning Model May Help Stratify Risk for Patients with Endometrial Cancer

  • Presented by Sarah Fremond, MSc, Leiden University Medical Center

Exome Sequencing Identifies Individuals With Cancer Predisposition Syndromes Missed by Current Screening Guidelines

  • Presented by N. Jewel Samadder, MD, Mayo Clinic College of Medicine, Mayo Clinic Comprehensive Cancer Center


A Liquid Biopsy-based Multicancer Early Detection Test May Detect Early-stage Disease and Low DNA-shedding Cancers

  • Presented by Ben Ho Park, MD, PhD, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center

Single-agent Pembrolizumab May Benefit Patients with Rare Type of Skin Cancer

  • Presented by Kari Kendra, MD, PhD, Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Lung Cancer Incidence Rates Varied Significantly Among Florida’s Black and Hispanic Ethnic Subgroups

  • Presented by Hannah M. Cranford, MPH, University of Miami School of Medicine

Brain Metastases in Patients with Kidney Cancer May Have Immune-suppressive Tumor Microenvironments

  • Presented by Elshad Hasanov, MD, PhD, The University of Texas MD Anderson Cancer Center